OK, full disclosure. ... but it ain't no Chevette/
Post# of 11803
(Total Views: 321)
Posted On: 02/20/2019 10:06:31 AM
OK, full disclosure. ... but it ain't no Chevette/Pinto/Pacer.
Wait just a damm minute. I bought a 1971 Pinto brand new my first year at ND. I paid $1895.00 and the dealer threw in a free undercoat. The Pinto had a 2000cc Porshe engine in it and it ran like an SOB. Ford used that engine because their POS 2300cc engine was not ready until 1973. I put a capacitive discharge system in the Pinto (that I still have). I put 162,000 miles on it and if it hadn't rusted through in the magical South Bend winters, I would still have that car. The best car I ever had.
Now as for the continuous monitoring product. I cannot tell you how many stock traders writing as technology experts are predicting DECN's doom and gloom, and they may be right. so much damage has been done to the stock and Mr. Berman's reputation by total frauds.
Continuous glucose monitoring the the U.S. and Canada is still 5 years away and 7-8 years away in Europe. Economies of scale have not entered the industry, there are still substandard products in the market and gumming up the FDA review system, and Medicare and the insurers have shown no desire to pay what the companies are charging. All of this has to change before these products are considered mainstream, no matter what a stock trader says.
Wait just a damm minute. I bought a 1971 Pinto brand new my first year at ND. I paid $1895.00 and the dealer threw in a free undercoat. The Pinto had a 2000cc Porshe engine in it and it ran like an SOB. Ford used that engine because their POS 2300cc engine was not ready until 1973. I put a capacitive discharge system in the Pinto (that I still have). I put 162,000 miles on it and if it hadn't rusted through in the magical South Bend winters, I would still have that car. The best car I ever had.
Now as for the continuous monitoring product. I cannot tell you how many stock traders writing as technology experts are predicting DECN's doom and gloom, and they may be right. so much damage has been done to the stock and Mr. Berman's reputation by total frauds.
Continuous glucose monitoring the the U.S. and Canada is still 5 years away and 7-8 years away in Europe. Economies of scale have not entered the industry, there are still substandard products in the market and gumming up the FDA review system, and Medicare and the insurers have shown no desire to pay what the companies are charging. All of this has to change before these products are considered mainstream, no matter what a stock trader says.
(1)
(0)